Equity Research Analysis: Repare Therapeutics Inc. (RPTX)
|Blank Capital Research Unit|Spot: $2.65
Price$2.65
Composite Score63.8/100
RatingHOLD (3★)
Rank#360 OF 7,333
Market Cap$76M
Intelligence Feed
citybizJan 29 Neutral
Repare Announces Completion of Acquisition by XenoTherapeutics
Repare Therapeutics Inc. has announced the completion of its acquisition by XenoTherapeutics, Inc. and Xeno Acquisition Corp. Shareholders received approximately US$2.20 per common share, plus one non-transferable contingent value right (CVR). The common shares are expected to cease trading on the Nasdaq Global Select Market around January 28, 2026.
TradingViewJan 28 Positive
Repare Therapeutics Announced Transfer or Voluntary Withdrawal of Listing
Repare Therapeutics announced its intention to delist and deregister its shares from Nasdaq following the closing of a transaction on January 28, 2026. The company requested a suspension of trading and will file Form 25 for delisting, with the purchaser also planning to file Form 15 to terminate SEC reporting obligations. This action follows an original SEC Filing by Repare Therapeutics Inc. (RPTX) on the same date.
TipRanksJan 16 Positive
Repare Therapeutics Shareholders Approve Acquisition by XenoTherapeutics
Repare Therapeutics shareholders have approved the acquisition of all outstanding common shares by XenoTherapeutics Inc., a non-profit biotechnology group, with 99.76% of votes in favor. They also approved executive compensation related to the transaction and contingency plans for liquidation through KPMG if the deal fails. The recent analyst rating for RPTX stock is a Hold with a $3.00 price target, while TipRanks’ AI Analyst, Spark, rates it Neutral due to weak financial performance tempered by a strong balance sheet and positive corporate developments.
Investing.comDec 25 Positive
Repare Therapeutics stock soars after Gilead Sciences deal for cancer drug
Repare Therapeutics stock surged 18% in premarket trading after announcing a definitive asset purchase agreement with Gilead Sciences for its cancer drug RP-3467. The deal includes up to $30 million in consideration, enhancing Repare's cash balance and increasing the estimated per-share payout for shareholders in its upcoming acquisition by XenoTherapeutics to approximately $2.20. This marks Repare's third and most significant portfolio transaction of the year.
NasdaqDec 25 Negative
Repare Therapeutics Sells Polymerase Theta ATPase Inhibitor To Gilead For Up To $30Mln
Repare Therapeutics (RPTX) has sold its polymerase theta ATPase inhibitor, RP-3467, to Gilead Sciences (GILD) for up to $30 million. This deal, which includes a $25 million upfront payment, strengthens Repare's cash balance and is expected to impact its pending acquisition by Xeno Therapeutics, with shareholders potentially receiving US$2.20 per share. RP-3467 is being evaluated in the POLAR Phase 1 trial for various advanced cancers, and the acquisition highlights Gilead's focus on oncology and synthetic lethality.